serratamolide

AT514, also known as serratamolide, is a natural cyclic depsipeptide derived from the bacterium *Serratia marcescens*. It is currently being investigated as a potential antineoplastic agent, particularly for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) and breast cancer. The compound exerts its effects by inducing cell cycle arrest and triggering the intrinsic apoptotic pathway. Mechanistically, AT514 interferes with survival signaling mediated by phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC), while also decreasing the activity of the transcription factor NF-κB. As a research-stage compound, it demonstrates selective toxicity toward malignant cells, with an average IC50 of 13 μM in B-CLL cells.

Other names

serratamolide